Autism Etiology and Individualized Care

Abstract

Families encounter competing explanations of autism and treatments promoted as correcting an underlying cause. A percentage breakdown could appear useful, but genetic liability, metabolic findings, environmental exposures, and treatment response describe different quantities and can overlap within the same child. My objective in this study is to examine which quantitative statements about autism etiology are defensible and how this evidence should inform expectations for individualized care. I use a targeted narrative review examining human genetic, epidemiological, mechanistic, and intervention research, together with clinical guidance and regulatory updates available in May 2026. Including reported estimates were retained with their original denominators and study contexts; incompatible measures were not pooled. My findings were that a large multinational study estimated autism heritability at 80.8%. Clinical genetic testing identifies explanatory findings in a smaller, selected proportion. No validated population fraction can be assigned to impaired methylation, blood–brain barrier dysfunction, or generalized chemical exposure. Small methylcobalamin and folinic-acid trials do not establish causal subtypes. However FOLR1-related cerebral folate transport deficiency provides a specific example of a treatable genetic disorder. Large studies and current international review evidence do not seem to support vaccines as a cause of autism. A direct study on the topic needs to be done for more details. Etiologic information can sometimes change care, but treatment should be selected by clinical findings, credible evidence, and meaningful goals. Nonresponse to a supplement does not diagnose another cause or establish that further experimental therapies will help.